SCHEMBL420472

SCHEMBL420472

Cc1ccc(S(=O)(=O)N(C)N)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
MCOLN3 Q8TDD5 1/20 0.61
C5AR1 P21730 1/20 0.57
AGER Q15109 1/20 0.57
CA12 O43570 3/20 0.55
CA9 Q16790 3/20 0.55
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA3 P07451 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
GAA P10253 2/20 0.52
ATM Q13315 1/20 0.50
GLA P06280 1/20 0.48
LMNA P02545 3/20 0.47
TLR9 Q9NR96 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24770891 0.84 CA12 (0.62) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL4402780 0.84 MAPT (0.57) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL82589 0.81 MAPT (0.65) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL5880406 0.81 MAPT (0.65) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL26413518 0.81 MAPT (0.65) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL29290107 0.80 AGER (0.55) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL7753501 0.80 MAPT (0.53) MAPTMCOLN3C5AR1AGERCA12
SCHEMBL13465714 0.80 KMT2A (0.49) MAPTCA1CA2GAALMNA
SCHEMBL7466825 0.80 CA12 (0.64) MAPTCA12CA9CA1CA2
SCHEMBL6431664 0.79 APOBEC3G (0.54) C5AR1CA12CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1318402-C Pyrrolidine-2-carboxylic acid hydrozide derivatives for use as metalloprotease inhibitors HOFFMANN LA ROCHE (CH) 2007-05-30 CN claimed
CN-1443163-A Pyrrolidine-2-carboxylic acid hydrazide derivatives as metalloproteinase inhibitors HOFFMANN LA ROCHE (CH) 2003-09-17 CN claimed
US-9115065-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses Kineta, Inc. (US) 2015-08-25 US disclosed
US-9067873-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Kineta Four, LLC (US) 2015-06-30 US disclosed
US-20140378681-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES INC. (US) 2014-12-25 US disclosed
US-20140275037-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2014-09-18 US disclosed
US-8664274-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses SIGA TECHNOLOGIES, INC. (US) 2014-03-04 US disclosed
US-8658697-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SIGA TECHNOLOGIES, INC. (US) 2014-02-25 US disclosed
US-8642596-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses SIGA TECHNOLOGIES, INC. (US) 2014-02-04 US disclosed
US-20130261087-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES SIGA TECHNOLOGIES INC. (US) 2013-10-03 US disclosed
US-8410149-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SIGA TECHNOLOGIES INC. (US) 2013-04-02 US disclosed
US-20090203675-A1 Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses SIGA TECHNOLOGIES, INC. (US) 2009-08-13 US disclosed
CN-1318402-C Pyrrolidine-2-carboxylic acid hydrozide derivatives for use as metalloprotease inhibitors HOFFMANN LA ROCHE (CH) 2007-05-30 CN disclosed
CN-1443163-A Pyrrolidine-2-carboxylic acid hydrazide derivatives as metalloproteinase inhibitors HOFFMANN LA ROCHE (CH) 2003-09-17 CN disclosed
EP-0922043-B1 PESTICIDAL 3-(SUBSTITUTED PHENYL)-5-(THIENYL OR FURYL)-1,2,4-TRIAZOLES DOW AGROSCIENCES LLC (US) 2002-01-30 EP disclosed
US-6262305-B1 Process and intermediates for preparing 3-(substituted phenyl)-5-(thienyl or furyl)-1,2,4-triazole compounds DOW AGROSCIENCES LLC 2001-07-17 US disclosed
US-6015826-A INSECTICIDES, APHIDICIDES, AND MITICIDES DOW AGROSCIENCES LLC 2000-01-18 US disclosed
EP-0922043-A1 PESTICIDAL 3-(SUBSTITUTED PHENYL)-5-(THIENYL OR FURYL)-1,2,4-TRIAZOLES Dow AgroSciences LLC (US) 1999-06-16 EP disclosed
WO-1998047894-A1 PESTICIDAL 3-(SUBSTITUTED PHENYL)-5-(THIENYL OR FURYL)-1,2,4-TRIAZOLES DOW AGROSCIENCES LLC (US) 1998-10-29 WO disclosed
US-4892887-A ANTITUMOR YALE UNIVERSITY (US) 1990-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275037-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES GBA1, GK, GCK MAPT 949/4885MCOLN3 3105/4885C5AR1 4548/4885
US-20140378681-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES GBA1, GK, GCK MAPT 949/4885MCOLN3 3105/4885C5AR1 4548/4885
US-20130261087-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES SORD, GBA1, GK MAPT 335/4885MCOLN3 3355/4885C5AR1 4366/4885
US-20090203675-A1 Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses GBA1, GK, GCK MAPT 896/4885MCOLN3 3166/4885C5AR1 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.